Guru Sonpavde, MD, of the Advent Health Cancer Institute, provides a preview of the 2024 ASCO Genitourinary Cancers Symposium. Dr. Sonpavde highlights what he is most looking forward to from this year’s meeting, and details several of the meeting’s key presentations, including results from the CONTACT-2 and KEYNOTE-564 studies.
Dr. Sonpavde also highlights the EMBARK study on outcomes for men with prostate cancer who suspend enzalutamide monotherapy treatment and the LITESPARK-005 trial evaluating subcutaneous nivolumab versus intravenous nivolumab for patients with clear cell renal carcinoma.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.